Virtual MOUD Treatment: Virtual Point-of-Care Toxicology Testing to Accompany Virtual Medication Assisted Treatment for Opioid Use Disorder

虚拟 MOUD 治疗：虚拟护理点毒理学测试伴随阿片类药物使用障碍的虚拟药物辅助治疗

• 批准号: 10316571
• 负责人: ERIC HERMES
• 金额: --
• 依托单位: VA CONNECTICUT HEALTHCARE SYSTEM
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-01 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10316571
• 关键词: Abstinence; Address; American; Behavior Therapy; Buprenorphine; Caring; Characteristics; Clinical; Computerized Medical Record; Connecticut; Consolidated Framework for Implementation Research; Data; Data Analyses; Data Collection; Diagnostic Reagent Kits; Documentation; Drug Prescriptions; Drug usage; Education; Feedback; Future; Goals; Healthcare Systems; Hybrids; Institution; Intervention; Interview; Laboratories; Leadership; Liquid substance; Massachusetts; Medical Records; Medicine; Methodology; Methods; Modality; Opioid; Oral; Outcome; Outpatients; Patient Schedules; Patient-Centered Care; Patient-Focused Outcomes; Patients; Persons; Pharmaceutical Preparations; Phase; Policies; Privacy; Procedures; Process; Provider; Publishing; Randomized; Randomized Clinical Trials; Reading; Regulation; Research; Resources; Saliva; Sampling; Secure; Self Administration; Services; Site; Societies; Specific qualifier value; Stigmatization; Structure; Substance Use Disorder; Telephone; Test Result; Testing; Time; Toxicology; Travel; United States Department of Veterans Affairs; Urine; Veterans; Visit; Visualization; addiction; arm; base; contingency management; design; drug of abuse; drug testing; effectiveness evaluation; health service use; improved; innovation; medication-assisted treatment; meetings; multi-site trial; novel; opioid use disorder; pandemic disease; pilot trial; point of care; point of care testing; randomized effectiveness trial; randomized trial; scale up; self testing; social stigma; substance use; testing uptake; trend; uptake; usability; user centered design; virtual; virtual delivery; virtual healthcare

Background. Medication treatment of Opioid Use Disorder (MOUD) saves lives and is increasingly delivered virtually. Currently, 60% of VA outpatient addiction treatment occurs over video. The pandemic accelerated this trend, but it will be sustained through multiple VA policies. However, toxicology testing, a major component of MOUD care, currently requires in-person visits. A process for virtual point-of-care toxicology testing is needed. Significance. In current virtual MOUD care, toxicology testing is either not completed or requires in-person urine testing, which is inconvenient and stigmatizing. A process for virtual point-of-care testing, which mitigates these barriers, will be developed through this research. Such as process will be more acceptable, facilitate patient-centered care, and decrease stigma, improving MOUD utilization and patient outcomes. This research will directly address VA stated goals to “Improve MOUD implementation” and “Understand how to address stigma.” Innovation. MOUD care, which incorporates (1) virtual toxicology testing, (2) patient self-testing at the point-of- care, and (3) oral-fluid test kits, is entirely novel. There has been no research on virtual point-of-care toxicology testing among Veterans. In addition, virtual toxicology testing will advance other innovative addiction treatments such as virtual contingency management. Specific Aims. This research will develop a Virtual Point-of-Care Toxicology Testing Process for VA. AIM 1 (Pre-Pilot) will design and iteratively modify a Virtual Toxicology Testing Process, which uses oral fluid test kits. AIM 2 (Pilot Trial) will evaluate the feasibility, acceptability, and proximal effects of the process by evaluating provider and patient testing uptake, qualitative feedback, and health service use. AIM 3 (Scale-up) will (1) prepare a Virtual Point-of-Care Toxicology Testing Toolkit and (2) operationalize testing for a future multi-site randomized trial. Methodology. Mixed-methods will be used to develop and evaluate the testing process, which will use an oral- fluid test for common drugs of abuse. Patients will self-administer the test during virtual MOUD visits and assess results with providers. In the pre-pilot phase, stakeholder groups of VA-wide clinical/laboratory leaders, providers, and patients will design and iteratively modify the process. In the pilot phase, a single-arm mixed- methods pilot trial will evaluate the process among patients and providers at two VA facilities. Feasibility will be evaluated by examining process uptake. Acceptability will be evaluated through semi-structured interviews with patients and providers based on Consolidated Framework for Implementation Research (CFIR) constructs. Health service use will be evaluated by analyzing data on patient characteristics, test utilization, and treatment contacts extracted from the electronic medical record. In the scale-up phase, the Virtual Point-of-Care Toxicology Testing Process will be summarized in a toolkit for VA-wide distribution. The toolkit will (1) identify tests meeting VA requirements; (2) develop education materials; (3) specify procedures for administering and analyzing tests; and (4) specify additional activities such as confirming results, ordering tests, and documenting results. Next Steps/Implementation. The Virtual Point-of-Care Toxicology Testing Toolkit will be disseminated using current VA addictions informational and didactic resources and venues. The toolkit will be operationalized for a future multisite, randomized hybrid trial evaluating the effectiveness of virtual toxicology testing compared to testing as usual.

背景。阿片类药物使用障碍（mod）的药物治疗可以挽救生命，并且越来越多地交付